For most children diagnosed with medulloblastoma, the most common malignant pediatric brain tumor, survival rates are encouraging. But for a subset, remission is not the end of the story. Roughly 30% ...

Stopping cancer from coming back is the goal of new research from MUSC Hollings Cancer Center, where scientists are targeting cells that fuel the return of an aggressive pediatric brain tumor.

A new review brings attention to the STING pathway as a critical regulator in both colitis and colon cancer, highlighting its complex and often opposing roles in inflammation and tumor development.

Immunotherapy has transformed cancer care, offering a way to harness the body’s own immune system to fight tumors. But even with these advances, many patients still don’t respond. One major barrier to ...

A new study leverages a modified pyrvinium hybrid to block GLI and WNT pathways, halting pediatric medulloblastoma relapse.

The researchers used lipid nanoparticles (LNPs) to deliver cyclic GMP-AMP (cGAMP) synthase (cGAS) mRNA to cancer cells. This results in production of the endogenous stimulator of interferon genes ...

Kinases that shuttle cholesterol within tumor cells help fuel growth. Blocking these enzymes may starve cancer cells, ...

A new study suggests that Resmetirom may do more than treat fatty liver disease — it could also help stop liver cancer from ...

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...